Income StatementBalance SheetCash FlowSegments
Boston Scientific logo

Boston Scientific Cash Flow Statement

Operating, investing, and financing cash movements

Boston Scientific generated $4.3B in operating cash flow over the trailing twelve months. After $866.0M in capital expenditures, free cash flow was $3.5B. Free cash flow increased 0.2% year-over-year. Based on the Q1 2026 filing.

Net Cash From Operating (TTM)$4.3BNet Cash From Investing (TTM)-$2.7BNet Cash From Financing (TTM)-$888.0MCapital Expenditures (TTM)$866.0MDepreciation And Amortization Cf (TTM)$1.4BNet Change In Cash (TTM)$723.0M
Latest FilingQ1 2026
Report Date2026-05-01
Market Cap$79.6B
P/E Ratio22.36
ROE14.81%

Investing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Acquisitions, net of cash acquired$3.4B$239.0M$1.0B$256.0M$89.0M$523.0M
Capital expenditures$277.0M$187.0M$157.0M$181.0M$351.0M$177.0M
Payment for (Proceeds from) Other Investing Activity-$4.0M-$3.0M-$4.0M-$4.0M-$73.0M-$48.0M
Proceeds from (payments for) investments and acquisitions of certain technologies$16.0M$77.0M$33.0M$70.0M$74.0M-$61.0M
Net cash from investing activities-$3.7B-$500.0M-$1.1B-$502.0M-$512.0M-$591.0M

Operating

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Change in accounts payable$385.0M-$385.0M$231.0M$165.0M$285.0M-$512.0M
Change in accounts receivable$90.0M$107.0M$32.0M$32.0M$98.0M$117.0M
Change in inventories—$109.0M-$65.0M$94.0M$50.0M$177.0M
Other working capital changes$52.0M-$7.0M$79.0M-$50.0M$20.0M$27.0M
Depreciation and amortization$348.0M$325.0M$336.0M$342.0M$365.0M$351.0M
Net cash from operating activities$1.5B$541.0M$1.3B$1.3B$1.4B$348.0M
Net income$563.0M$672.0M$795.0M$755.0M$670.0M$1.3B
Contingent consideration fair value adjustments-$1.0M$5.0M-$5.0M$11.0M$7.0M-$30.0M
Deferred and prepaid income taxes-$80.0M$41.0M-$90.0M$69.0M-$22.0M-$351.0M
Gain (Loss) on Investments-$19.0M-$28.0M$219.0M-$10.0M—$158.0M
Increase (Decrease) in Other Operating Assets$17.0M$77.0M$31.0M-$5.0M—$109.0M
Inventory step-up amortization$51.0M$81.0M$37.0M$9.0M$5.0M$2.0M
Stock-based compensation$69.0M$74.0M$75.0M$79.0M$71.0M$83.0M

Financing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Finance Lease, Principal Payments$0.0$36.0M$6.0M$7.0M$209.0M$0.0
Payment to net share settle employee equity awards$4.0M$118.0M$5.0M$5.0M$3.0M$85.0M
Proceeds From Issuance Of Senior Long Term Debt$0.0$1.6B$0.0$0.0$0.0$0.0
Other, net-$250.0K-$10.0M$9.0M-$1.0M$9.0M$3.0M
Proceeds from (repayments of) short-term borrowings, net$187.0M-$192.0M———$0.0
Proceeds from issuance of common stock relating to employee stock plans$28.0M$115.0M$32.0M$115.0M$20.0M$81.0M
Repayments of Short-Term Debt$0.0$1.1B$500.0M$12.0M$0.0$259.0M
Net cash from financing activities$214.0M$233.0M-$340.0M-$104.0M-$184.0M-$260.0M

Free Cash Flow

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Free cash flow$1.2B$354.0M$1.1B$1.2B$1.0B$171.0M

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Effect of exchange rate changes on cash-$9.0M$39.0M$2.0M-$2.0M$3.0M$0.0
Net increase (decrease) in cash-$2.0B$314.0M-$179.0M$735.0M$671.0M-$504.0M

Supplemental

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Income taxes paid$164.0M$140.3M$140.3M$140.3M$140.3M—
Interest paid$62.5M$79.8M$79.8M$79.8M$79.8M—
ROU Asset Obtained for Lease Liability$29.3M$29.8M$29.8M$29.8M$29.8M—